## Clinical Context This patient has type 2 diabetes with atherogenic dyslipidemia (elevated triglycerides, low HDL-C, elevated LDL-C) and meets criteria for statin therapy regardless of baseline lipid levels. ## Rationale for Correct Answer **Key Point:** In patients with type 2 diabetes, statins are indicated for primary prevention of cardiovascular disease. The ATP III and current ACC/AHA guidelines recommend statin therapy for all diabetic patients aged 40–75 years, irrespective of baseline LDL-C levels, unless contraindicated. **High-Yield:** Atorvastatin 40 mg is a moderate-intensity statin appropriate for this patient's risk category. Reassessment at 6 weeks allows evaluation of LDL-C response and tolerability before dose adjustment. ## Why This Approach 1. **Immediate statin initiation** is evidence-based for diabetic patients with dyslipidemia 2. **No need for coronary angiography** in asymptomatic patients without acute coronary syndrome 3. **Glycemic control optimization** is important but does not delay statin initiation — both should proceed in parallel 4. **Fibrate monotherapy** is not first-line; statins are the cornerstone of lipid management in diabetes ## Management Algorithm ```mermaid flowchart TD A[Type 2 DM + Dyslipidemia]:::outcome --> B{Age 40-75 yrs?}:::decision B -->|Yes| C[Initiate statin]:::action C --> D[Moderate-intensity: Atorvastatin 40 mg]:::action D --> E[Recheck lipids at 6 weeks]:::action E --> F{LDL-C at goal?}:::decision F -->|Yes| G[Continue + optimize glycemia]:::outcome F -->|No| H[Uptitrate or add ezetimibe]:::action ``` **Clinical Pearl:** Atorvastatin 40 mg typically reduces LDL-C by 40–50%; if LDL-C goal is not met, escalation to 80 mg or addition of ezetimibe is the next step. Fibrates are reserved for severe hypertriglyceridemia (>500 mg/dL) or as adjunctive therapy when statin + ezetimibe fails. [cite:Harrison 21e Ch 402] 
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.